 |
196 Products |  |
52 Diseases | | 196 Products |
|
3529 Trials |  |
15381 News |  |
| «12...4142434445464748495051...208209» |
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P3 trial: A multicenter, prospective, cohort study exploring the efficacy and safety of portal vein ligation combined with hepatic arterial infusion chemotherapy and systemic therapy versus ALPPS in the conversion treatment of hepatocellular carcinoma with inadequate future-liver-remnant (EUDRACT) - Apr 2, 2025
P3, N=110, Not yet recruiting, Sponsor: The First Affiliated Hospital of Guangxi Medical University; The First Affiliated Hospital of Guangxi Medical University
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Hepatic arterial infusion chemotherapy (HAIC) combined with carrilizumab and apatinib mesylate conversion therapy for unresectable hepatocellular carcinoma with portal vein cancer thrombus is an open, single-arm, multicenter, prospective clinical study (EUDRACT) - Apr 2, 2025
P2, N=13, Not yet recruiting, Sponsor: Drum Tower Hospital; Drum Tower Hospital
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: A single-arm, multicenter, exploratory clinical study of adebelimab in combination with chemotherapy in the neoadjuvant treatment of esophageal squamous cell carcinoma (EUDRACT) - Apr 2, 2025
P2, N=55, Not yet recruiting, Sponsor: Cancer Hospital Affiliated to Shandong First Medical University; Cancer Hospital Affiliated to Shandong First Medical University
- | Lonsurf (trifluridine/tipiracil) / Otsuka, AiTan (rivoceranib) / HLB Bio Group
New P2 trial: TAS102 in combination with apatinib mesylate tablets for advanced third and higher line HER2-negative gastric/esophagogastric union adenocarcinoma: a prospective, multicenter, single-arm study (EUDRACT) - Apr 2, 2025
P2, N=38, Not yet recruiting, Sponsor: The First Hospital of Shanxi Medical University; The First Hospital of Shanxi Medical University
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: Phase II clinical study of adebrelimab plus apatinib and SOX regimen for conversion therapy of advanced gastric or gastroesophageal junction adenocarcinoma (EUDRACT) - Apr 2, 2025
P2, N=49, Recruiting, Sponsor: Beijing Friendship Hospital, Capital Medical University; Beijing Friendship Hospital, Capital Medical University
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate in Advanced Pancreatic Cancer:A Multi-center, Single-arm, Phase II Exploratory Trial (EUDRACT) - Apr 2, 2025
P2, N=43, Recruiting, Sponsor: The FIrst Affiliated Hospital, College of Medicine, Zhejiang University; The FIrst Affiliated Hospital, College of Medicine, Zhejiang University
- | TheraCIM (nimotuzumab) / Daiichi Sankyo, Oncoscience, Biocon, HRS-4642 / Jiangsu Hengrui Pharma
New P1/2 trial: HRS-4642 combined with Nimotuzumab in the treatment of recurrent or metastatic pancreatic ductal adenocarcinoma with KRAS G12D mutation that has failed systemic therapy (EUDRACT) - Apr 2, 2025
P1/2, N=10, Recruiting, Sponsor: West China Hospital,Sichuan University; West China Hospital,Sichuan University
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
New trial: Efficacy and safety of dalsiris in combination with an adjuvant aromatase inhibitor in patients with HR+/HER2- locally advanced breast cancer: a multicenter, cohort study (EUDRACT) - Apr 2, 2025
P=N/A, N=300, Not yet recruiting, Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University o
- | Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
New trial: A clinical study protocol of hetrombopag combined with immunosuppressants for the treatment of severe aplastic anemia in children (EUDRACT) - Apr 2, 2025
P=N/A, N=68, Not yet recruiting, Sponsor: Wuhan Children's Hospital affiliated to Tongji Medical College, Huazhong University of Science and Technology; Wuhan Children's Hospital affiliated to
- | remimazolam tosylate (HR-7056) / Jiangsu Hengrui Pharma
New P1 trial: Comparison of Remimazolam and Propofol for Reducing Postoperative Delirium in Pediatric Otolaryngology Surgery: A Randomized Non-Inferiority Trial (EUDRACT) - Apr 2, 2025
P1, N=80, Recruiting, Sponsor: Affiliated Hospital of North Sichuan Medical College; Affiliated Hospital of North Sichuan Medical College
- | remimazolam tosylate (HR-7056) / Jiangsu Hengrui Pharma
New trial: Comparison of EEG Burst Suppression and Hemodynamic Effects Between Remimazolam tosilate and Etomidate During General Anesthesia Induction (EUDRACT) - Apr 2, 2025
P=N/A, N=161, Recruiting, Sponsor: The Second People
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New trial: A randomized, controlled, multicenter Phase II clinical study comparing neoadjuvant chemotherapy and immunotherapy and immuno-consolidationafter compared with immunoconsolidation after radical chemoradiotherapy for stage III potentially resectable NSCLC (EUDRACT) - Apr 2, 2025
P=N/A, N=92, Recruiting, Sponsor: Zhejiang Cancer Hospital; Zhejiang Cancer Hospital
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma
New P4 trial: Clinical Study on the Safety and Efficacy of Pyrotinib Combined with Dexamethasone in the Treatment of Relapsed and Refractory Multiple Myeloma (EUDRACT) - Apr 2, 2025
P4, N=47, Not yet recruiting, Sponsor: The First Affiliated Hospital of Fujian Medical University; The First Affiliated Hospital of Fujian Medical University
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P4 trial: A single arm, exploratory study on the combination of Adebrelimab and Apatinib as adjuvant therapy for hepatocellular carcinoma patients at high risk of recurrence after resection surgery (EUDRACT) - Apr 2, 2025
P4, N=30, Not yet recruiting, Sponsor: Qilu Hospital of Shandong University; Qilu Hospital of Shandong University
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P4 trial: The relationship between body composition and the efficacy of Camrelizumab in the treatment of solid tumors?a observational study (EUDRACT) - Apr 2, 2025
P4, N=60, Not yet recruiting, Sponsor: The first people's hospital of ziyang; The first people's hospital of ziyang
- | AiTan (rivoceranib) / HLB Bio Group
New P2 trial: Exploratory clinical study of Irinotecan Liposome combined with Vincristine and Apatinib in the treatment of relapsed/refractory rhabdomyosarcoma in adult. (EUDRACT) - Apr 2, 2025
P2, N=31, Not yet recruiting, Sponsor: Beijing Cancer Hospital; Beijing Cancer Hospital
- | remimazolam tosylate (HR-7056) / Jiangsu Hengrui Pharma
New P4 trial: Effect of Remimazolam Tosilate on Hemodynamics During Induction of Anesthesia in Patients Undergoing Off-Pump Coronary Artery Bypass Grafting (EUDRACT) - Apr 2, 2025
P4, N=168, Not yet recruiting, Sponsor: Jining No.1 People's Hospital; Jining No.1 People's Hospital
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
New P4 trial: To evaluate the efficacy of trastuzumab + pyrotinib + dalpiciclib (EUDRACT) - Apr 2, 2025
P4, N=161, Not yet recruiting, Sponsor: Xiangya Hospital, Central South University; Xiangya Hospital, Central South University
- | remimazolam tosylate (HR-7056) / Jiangsu Hengrui Pharma
New P4 trial: Effects of remimazolam tosylate on early postoperative memory in young and middle-aged patients undergoing laparoscopic surgery (EUDRACT) - Apr 2, 2025
P4, N=228, Not yet recruiting, Sponsor: Department of Anesthesiology, The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital); The First Af
- | AiTan (rivoceranib) / Elevar Therapeutics, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New trial: An exploratory clinical study of radiotherapy sequential Adebrelimab and apatinib in the treatment of HR+/ HER2-advanced CDK4/6 inhibitors in patients with breast cancer (EUDRACT) - Apr 2, 2025
P=N/A, N=30, Recruiting, Sponsor: The First Affiliated Hospital of Chongqing Medical University; The First Affiliated Hospital of Chongqing Medical University
- | AiRuiKa (camrelizumab) / HLB Bio Group, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New trial: A multicenter, cohort, prospective clinical study of adebelimab or carilizumab combined with icariin soft capsules and gemcitabine/cisplatin (GemCis) in the treatment of initially unresectable advanced biliary tract tumors (BTC) (EUDRACT) - Apr 2, 2025
P=N/A, N=60, Not yet recruiting, Sponsor: Lanzhou University Second Hospital (Second Clinical School); Lanzhou University Second Hospital (Second Clinical School)NIVERSITY
- | remimazolam tosylate (HR-7056) / Jiangsu Hengrui Pharma
New P4 trial: The Median Effective Dose and studies on Pharmacokinetics of Afentanil combined with Remimazolam Tosilate for hysteroscopic Surgery (EUDRACT) - Apr 2, 2025
P4, N=100, Not yet recruiting, Sponsor: Qingdao Women and Children's hospital; Qingdao Women and Children's hospital
- | SHR-A2102 / Jiangsu Hengrui Pharma, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: An exploratory trial of SHR-A2102 in combination with Adebrelimab for the treatment of unresectable stage III non-small cell lung cancer (EUDRACT) - Apr 2, 2025
P2, N=20, Not yet recruiting, Sponsor: Shanghai Chest Hospital; Shanghai Chest Hospital
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Neoadjuvant Camrelizumab Combined with Chemotherapy for Thoracic Esophageal Squamous Cell Carcinoma with Cervical Lymph Node Metastasis: A Single Arm Phase II Study. (EUDRACT) - Apr 2, 2025
P2, N=33, Not yet recruiting, Sponsor: Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
- | AnDaJing (vunakizumab) / Jiangsu Hengrui Pharma
New trial: IL-17 pathway inhibitor Vunakizumab for the treatment of systemic sclerosis: a single arm, open label trial (EUDRACT) - Apr 2, 2025
P=N/A, N=5, Not yet recruiting, Sponsor: The Second Xiangya Hospital, Central South University; The Second Xiangya Hospital, Central South University
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P4 trial, Real-world evidence: A multicenter, prospective, interventional, real-world study on the impact of ARBs on the efficacy of Camrelizumab combined with chemotherapy as first-line treatment for advanced non-small cell lung cancer (EUDRACT) - Apr 2, 2025
P4, N=180, Not yet recruiting, Sponsor: Wuxi people
- | SHR-1703 / Jiangsu Hengrui Pharma
New trial: A randomized, double-blind, placebo-controlled clinical study evaluating the efficacy and safety of subcutaneous injection of SHR-1703 in patients with allergic bronchopulmonary aspergillosis (ABPA) (EUDRACT) - Apr 2, 2025
P=N/A, N=21, Not yet recruiting, Sponsor: West China Hospital of Sichuan University; West China Hospital of Sichuan University
- | Avastin (bevacizumab) / Roche
New trial: Chemoradiotherapy plus immunotherapy with or without low-dose bevacizumab in first-line treatment of patients with brain metastases from driver gene-negative non-small cell lung cancer: a single-center, randomized controlled, open-label, prospective clinical study (EUDRACT) - Apr 2, 2025
P=N/A, N=60, Not yet recruiting, Sponsor: Chongqing university cancer hospital; Chongqing university cancer hospital
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New trial: Prospective, single-center exploratory study of radical chemoradiotherapy (dCRT) combined with adbelizumab sequential adbelizumab combined with irinotecan liposomes in the treatment of unresectable advanced esophageal squamous cell carcinoma (EUDRACT) - Apr 2, 2025
P=N/A, N=5, Not yet recruiting, Sponsor: The Second Xiangya Hospital, Central South University; The Second Xiangya Hospital, Central South University
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New trial: A Single-Center, Single-Arm Exploratory Clinical Study of Adebrelimab Combined with Paclitaxel Liposome and Cisplatin as Neoadjuvant Therapy for Locally Advanced Cervical Cancer (EUDRACT) - Apr 2, 2025
P=N/A, N=47, Not yet recruiting, Sponsor: Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center
- | famitinib (SHR 1020) / Jiangsu Hengrui Pharma
New P2 trial: Efficacy and safety of famitinib in the treatment of unresectable advanced desmoid tumors: a prospective, single-arm clinical study (EUDRACT) - Apr 2, 2025
P2, N=42, Recruiting, Sponsor: Peking University Cancer Hospital; Peking University Cancer Hospital
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
New trial, Real-world evidence: Pyrotinib in T-DXD-treated HER2-positive advanced breast cancer: a prospective, single-arm, multicenter, real-world study (EUDRACT) - Apr 2, 2025
P=N/A, N=100, Not yet recruiting, Sponsor: The First Hospital of Jilin University; The First Hospital of Jilin University
- | AiRuiEn (rezvilutamide) / Jiangsu Hengrui Pharma
New trial, Real-world evidence: Real world research on Rezvilutamide (EUDRACT) - Apr 2, 2025
P=N/A, N=112, Not yet recruiting, Sponsor: Ruijin Hospital, Shanghai Jiao Tong University School of Medicine; Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
- | AiSuTe (tegileridine) / Jiangsu Hengrui Pharma
New trial: Evaluation of the clinical effect of tegileridine fumarate injection for postoperative analgesia after video-assisted thoracoscopic surgery: a single-center, randomized, double-blind, positive controlled study (EUDRACT) - Apr 2, 2025
P=N/A, N=114, Not yet recruiting, Sponsor: Chengdu Second People
- | Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
New trial: Comparison of the efficacy and safety of Hetrombopag and other thrombopoietin receptor agonists in the treatment of primary Immune thrombocytopenia (EUDRACT) - Apr 2, 2025
P=N/A, N=800, Not yet recruiting, Sponsor: West China Hospital, Sichuan University; West China Hospital, Sichuan University
- || AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis
Trial completion: A SHR0302 BA Study on Healthy Subjects (clinicaltrials.gov) - Apr 2, 2025
P1, N=16, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Active, not recruiting --> Completed
- | Ruiqin (henagliflozin) / Jiangsu Hengrui Pharma
New P4 trial: Cancelled by the investigator Effect of Henagliflozin on cardiac function and structure in HFpEF patients with combined type 2 diabetes mellitus (EUDRACT) - Apr 2, 2025
P4, N=40, Not yet recruiting, Sponsor: Department of Cardiovascular Medicine, Hubei Third People's Hospital; Hubei NO. 3 People
- | remimazolam tosylate (HR-7056) / Jiangsu Hengrui Pharma
New trial: Effect of remimazolam tosilate on Propofol-related Euphoria in upper gastrointestinal endoscopy:a prospective, randomized, double-blind, controlled clinical trial (EUDRACT) - Apr 2, 2025
P=N/A, N=600, Not yet recruiting, Sponsor: Northern Jiangsu People's Hospital; Northern Jiangsu People's Hospital
- |||||| SHR-2004 / Jiangsu Hengrui Pharma
Enrollment open: Phase III Clinical Study of SHR-2004 Injection in Preventing Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty (clinicaltrials.gov) - Apr 2, 2025
P3, N=1167, Recruiting, Sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New trial: Efficacy and safety of addebellizumab plus antilotinib as first-line treatment for STK11 and/or KEAP1-mutated advanced non-small cell lung cancer (EUDRACT) - Apr 2, 2025
P=N/A, N=37, Recruiting, Sponsor: Shanghai Pulmonary Hospital; Shanghai Pulmonary Hospital
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Cipterbin (inetetamab) / 3SBio
New P4 trial: Efficacy and Safety Study of Inetetamab and Pyrotinib Combined with Chemotherapy as First-Line Treatment for HER2-Expressing Advanced Cholangiocarcinoma (EUDRACT) - Apr 2, 2025
P4, N=24, Not yet recruiting, Sponsor: Beijing Chao-Yang Hospital, Capital Medical University; Beijing Chao-Yang Hospital, Capital Medical University
- | AiRuiKa (camrelizumab) / HLB Bio Group
New trial: Clinical study on the safety and efficacy of neoantigen mRNA drugs in patients with non-small cell lung cancer (EUDRACT) - Apr 2, 2025
P=N/A, N=9, Not yet recruiting, Sponsor: Third People's Hospital of Yancheng; Third People's Hospital of Yancheng
- | Sulanda (surufatinib) / Hutchmed, AiRuiKa (camrelizumab) / HLB Bio Group
New trial: Efficacy and safety study of Camrelizumab in combination with Surufatinib and irinotecan liposome(II) for the post-line treatment of advanced biliary tract cancer (EUDRACT) - Apr 2, 2025
P=N/A, N=34, Not yet recruiting, Sponsor: Peking University International Hospital; Peking University International Hospital
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: High- and low-dose radiotherapy combined with Adebrelimab for advanced solid tumors after failure of first-line therapy (EUDRACT) - Apr 2, 2025
P2, N=33, Not yet recruiting, Sponsor: Affiliated Hospital of Jiangnan University; Affiliated Hospital of Jiangnan University
- | remimazolam tosylate (HR-7056) / Jiangsu Hengrui Pharma
New trial: Application of remimazolam tosylate-based anesthesia in enhanced recovery for liver transplantation (EUDRACT) - Apr 2, 2025
P=N/A, N=120, Not yet recruiting, Sponsor: Affiliated Hospital of Qingdao University; Affiliated Hospital of Qingdao University
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma, HRS-4642 / Jiangsu Hengrui Pharma
Enrollment open, Monotherapy: A Study of HRS-4642 Monotherapy or in Combination With Adebrelimab in the Treatment of Advanced Biliary Tract Tumors. (clinicaltrials.gov) - Apr 2, 2025
P2, N=49, Recruiting, Sponsor: Shanghai Zhongshan Hospital
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
New P4 trial: A multicenter, prospective and open clinical study of pyrotinib maleate tablets combined with trastuzumab in adjuvant treatment of HER-2 positive early or locally advanced breast cancer (EUDRACT) - Apr 2, 2025
P4, N=200, Not yet recruiting, Sponsor: Henan Provincial People's Hospital; Henan Provincial People's Hospital
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New trial: A single-arm, multicenter, exploratory clinical study of concurrent/sequential chemoradiotherapy and immunoconsolidation therapy for stage III non-resectable non-small cell lung cancer after chemoimmunotherapy induction therapy (EUDRACT) - Apr 2, 2025
P=N/A, N=37, Not yet recruiting, Sponsor: Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology; Union Hospital Affiliated to Tongji Medical Colleg
- | AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, AiRuiKa (camrelizumab) / HLB Bio Group
Trial completion, Enrollment change: Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer (clinicaltrials.gov) - Apr 1, 2025
P2, N=106, Completed, Sponsor: Fujian Medical University
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | N=53 --> 106
- |||||||||| HRS-7535 / Kailera Therapeutics
New P3 trial: A Trial of HRS-7535 Tablets in Subjects With Overweight or Obesity (clinicaltrials.gov) - Apr 1, 2025
P3, N=550, Not yet recruiting, Sponsor: Shandong Suncadia Medicine Co., Ltd.